Associated tags: CNS, Patient, Therapy, Pharmaceutical industry, Terran, Brain, Neuropsychiatry, Depression, Patent, PCT
Locations: NEW YORK, CALIFORNIA, FLORIDA, UNITED STATES, NORTH AMERICA, US
Retrieved on:
Wednesday, December 20, 2023
Software,
Research,
Radiology,
Pharmaceutical,
Mental Health,
Technology,
Hospitals,
Health Technology,
Science,
Neurology,
Biotechnology,
FDA,
Health,
Psychiatry,
Associate,
MRI,
Locus coeruleus,
DSM-IV codes,
Physician,
Albert Einstein's brain,
Hospital,
Brain,
Doctor of Philosophy,
News,
PACS,
Substantia nigra,
Columbia University,
Mental Hygiene,
University,
Biomedicine,
CNS,
Molecular medicine,
Schizophrenia,
Assistant,
Patient,
Diagnosis,
Meta-analysis,
Neuroscience,
Therapy,
Algorithm,
Automation,
Medical imaging Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
Key Points:
- Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
- Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first.
- NM-101 is a cloud-based analysis platform that is able to seamlessly integrate into existing workflows at hospitals and imaging centers.
- NM-101 contains algorithms that enabled for the first time the fully automated analysis and the cross-scanner harmonization of neuromelanin MRI scans [8-10,12,13].
Men,
Research,
Other Health,
Pharmaceutical,
Consumer,
Mental Health,
Clinical Trials,
Science,
Biotechnology,
Alternative Medicine,
FDA,
Health,
Other Science,
Psilocybin,
Vomiting,
MAOI,
Depression,
Safety,
GMP,
Chemistry,
DMT,
Patient,
Therapy,
Nausea,
Hydrogen chloride,
Patent,
Blood pressure,
Pharmaceutical industry,
Terran Two of these patents cover the world’s first new forms of psilocybin (psilocybin HCl and psilocybin edisylate) and their method of use in treating neurological and psychiatric disorders, including depression.
Key Points:
- Two of these patents cover the world’s first new forms of psilocybin (psilocybin HCl and psilocybin edisylate) and their method of use in treating neurological and psychiatric disorders, including depression.
- The clinical trials of psilocybin to date have been limited to using the older forms of zwitterionic psilocybin described in the historical literature.
- Terran plans to use its new forms of psilocybin to pursue a rapid 505(b)(2) FDA approval pathway if one of the existing forms of psilocybin currently in clinical trials is approved.
- Terran believes this new discovery may be the most stable form of tabernanthalog monofumarate.
Drug Master File,
Pierre Fabre,
Half-life,
Schizophrenia,
Idazoxan,
CMC,
Clinical trial,
Pharmacokinetics,
DSM-IV codes,
CNS,
Plasma,
Patient,
XR,
FDA,
S.A.S,
Safety,
Pharmaceutical industry,
Terran The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.
Key Points:
- The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.
- Idazoxan has been tested in multiple phase 3 clinical studies and has been dosed in over 1,000 patients across a variety of neuropsychiatric indications.
- Dr. Sam Clark, Terran's founder and CEO remarked, "We are thrilled to partner with the team at Pierre Fabre and to push forward with the development of idazoxan and this pipeline of CNS compounds.
- Given the strength of the human data to date, we believe idazoxan XR has the potential to revolutionize the treatment of patients with schizophrenia and other neuropsychiatric disorders."
MDAI,
Therapy,
MEAI,
PTSD,
PCT,
MDE,
Literature,
Patent,
Post-traumatic stress disorder,
Patient,
USE,
MBDB,
Empathy,
Terran,
SALTS,
MDMA,
MDEA,
Pharmaceutical industry MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
Key Points:
- MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
- Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
- As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
- Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.
Psilocybin,
GMP,
Human,
Drug Master File,
Depression,
Therapy,
SOLID,
History,
PCT,
Literature,
Hydrogen chloride,
Patent,
Patient,
DMF,
Ecosystem,
Salt,
FDA,
Terran,
SALTS,
Pharmaceutical industry Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.
Key Points:
- Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.
- Recent clinical studies suggest psilocybin is efficacious in treating depression.
- According to the literature, there are three main polymorphic forms of zwitterionic psilocybin: form A, form B, and form A' (A-Prime).
- Terran also replicated this comprehensive set of studies with the psilocin prodrug O-acetylpsilocin, resulting in additional novel salts and polymorphs of that compound as well.
MDMC,
REMS,
MDAI,
Depression,
Therapy,
MDEA,
Mitigation,
Methylone,
Anxiety,
Therapeutic index,
Pathology,
Pharmacokinetics,
PCT,
MDE,
DSM-IV codes,
Literature,
OF,
Patent,
Patient,
Post-traumatic stress disorder,
USE,
MBDB,
Empathy,
Salt,
SALTS,
MDMA,
Safety,
Pharmaceutical industry,
Vaccine,
Terran,
PTSD The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
Key Points:
- The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
- Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
- Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
- Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.
Retrieved on:
Friday, February 24, 2023
Psilocybin,
Terran,
Prodrug,
Therapy,
Patent,
Patient,
Brain,
PCT,
Human,
Derivative,
Depression,
Pharmacokinetics,
Pharmaceutical industry NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering novel prodrugs of psilocin.
Key Points:
- NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering novel prodrugs of psilocin.
- Psilocin and psilocybin are both active compounds in psychedelic mushrooms, and psilocybin is the most well-studied prodrug of psilocin.
- Terran has designed novel, faster-acting prodrugs of psilocin that demonstrate a shorter duration of activity compared to psilocybin in animal studies.
- With new data from animal models published in this PCT patent application, Terran believes these prodrugs may represent the most comprehensive examples of improved prodrugs of psilocin compared to psilocybin.
Patent,
Brain,
MDMA,
Therapy,
Patient,
MAO,
Liver,
Monoamine oxidase,
Vomiting,
DMT,
Prodrug,
PCT,
Nausea,
Invention,
Terran,
Blood pressure,
Pharmacokinetics,
Pharmaceutical industry NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.
Key Points:
- NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.
- These applications highlight new data from animal studies demonstrating that DMT and 5-MeO-DMT can be made orally active through Terran's proprietary prodrug approach.
- With this new data from animal models, Terran believes these prodrugs may represent the first known examples of orally active forms of DMT and 5-MeO-DMT.
- Terran's MDMA approach is described in detail in the PCT patent application: "3,4-Methylenedioxymethamphetamine and related psychedelics and uses thereof" (WO/2023/283373).
NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
Key Points:
- NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
- These therapeutics generated 4 Investigational New Drug(IND) applicationsand over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.
- Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
- Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
Key Points:
- NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
- These therapeutics generated 4 Investigational New Drug(IND) applicationsand over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.
- Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
- Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
